Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06854341 · ClinicalTrials.gov registry record
A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 5,448
- Enrollment target
NCT06854341 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 5,448 participants.
The verdict
NCT06854341 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 5,448 participants
- Enrollment target
Study Summary
This was an observational, non-interventional, real world study involving secondary use of de-identified aggregate data from patients prescribed ofatumumab, collected by the Kesimpta Go Program in Canada. This study utilized a cohort design. The study period included all available data captured by the Kesimpta Go Program from program inception (April 2, 2021) to the time of data transfer (May 1, 2024). Patients were indexed into the study on the date they started their medication, from April 2, 2021 to May 1, 2024. The baseline period represented the period prior to ofatumumab treatment initiation. Baseline variables were collected from the enrollment form, which include demographic and clinical history, such as whether the patient had prior treatment with disease-modifying therapy (DMT). Patients were followed until the first of the following censoring events: ofatumumab discontinuation; end of the study period; or leaving the Kesimpta Go Program.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,448 participants |
| Start Date | 2024-02-09 |
| Est. Completion | 2024-08-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06854341
The ClinicalTrials.gov registry entry for NCT06854341 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,448 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06854341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06854341 about?
NCT06854341 is a clinical study titled "A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data". This was an observational, non-interventional, real world study involving secondary use of de-identified aggregate data from patients prescribed ofatumumab, collected by the Kesimpta Go Program in Canada. This study utilized a cohort design. The study period included all available data captured by t...
What is the current status of trial NCT06854341?
This trial is currently completed. The enrollment target is 5,448 participants. The study started on 2024-02-09. Estimated completion is 2024-08-27.
Who is sponsoring clinical trial NCT06854341?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.